A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.

Trial Profile

A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Erythropoietins; Granulocyte colony-stimulating factors
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms HOVON89MDS
  • Most Recent Events

    • 06 Dec 2016 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results of pre-final evaluation (n=180) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 16 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top